Better Health. Better Life.

Scientific Publication Highlights - trimeo-logo

Temporary Controllable Pseudobezoars: Non-Invasive Alternative to Surgical Gastric Volume Reduction for the Treatment of Obesity
Deneva MG, Marintchev A, Yadid-Pecht O, Fattouche M, Bray RC, Mintchev MP.
Gastroenterology, Volume 142, Issue 5, Supplement 1, Page S-131, 2012.
Presented on: Digestive Disease Week (DDW) 2012, San Diego, CA, USA, May 19 - 22, 2012.
Lecture by Professor Martin P. Mintchev on the opening day of DDW 2012, San Diego, USA.

Utilization of Temporary Controllable Intragastric Pseudobezoars for the Treatment of Obesity
Deneva MG, Yadid-Pecht O, Fattouche M, Mintchev MP.
Current Obesity Reports, 1(2), рр. 68-74, 2012.

Pseudofood (Temporary Controllable Gastric Pseudobezoars) as an Alternative to Intragastric Balloons for the Treatment of Obesity: Results from a Chronic Human Study
Mintchev MP, Deneva MG, Yadid-Pecht O, Fattouche M, and Bray RC.
Presented on: The Obesity Society: 28th Annual Scientific Meeting 2010, San Diego, CA, USA, October 8-12, 2010.

Pilot study of temporary controllable gastric pseudobezoars for dynamic non-invasive gastric volume reduction
Mintchev MP, Deneva MG, Mintchev, M.P., Deneva, M.G., Aminkov, B.I., Fattouche, M., Yadid-Pecht, O., Bray, R.C.
Physiological Measurement, Volume 31, Issue 2, Page(s) 131-144, 2010.

Pilot Studies of Temporary Controllable Gastric Pseudobezoars (Pseudofood) as an Alternative to Bariatric Surgery for the Treatment of Obesity
Mintchev, M.P., Deneva, M.G., Aminkov, B.I., Fattouche, M., Yadid-Pecht, O., Bray, R.C.
Gastroenterology 138 (5/1), p. S-755, 2010.


Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.